Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled WEgovy Real ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

3. A proposal under discussion seeks to extend the guaranteed employment under the Mahatma Gandhi National Rural Employment Guarantee Scheme (MGNREGS) from 100 to 125 days and to rename the flagship ...

Dr Joshi: Vigilance is the key. The drugs must be taken under strict supervision. Common side effects like nausea, vomitting, ...